trending Market Intelligence /marketintelligence/en/news-insights/trending/yHYgX-qCoOMA8YbL-c0NdQ2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

US FDA grants orphan status to miRagen's blood cancer drug

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


US FDA grants orphan status to miRagen's blood cancer drug

The U.S. FDA granted an orphan drug designation to miRagen Therapeutics Inc.'s product candidate MRG-106 for the treatment of mycosis fungoides, the most common form of a type of blood cancer called cutaneous T-cell lymphoma.

MiRagen's two lead product candidates MRG-106 and MRG-201 are currently in phase 1 clinical trials.